From the Department of Neurology (E.M.M.), Johns Hopkins University, Baltimore, MD; Department of Neurology (C.A., D.P.), University of Southern California, Los Angeles; Department of Epidemiology and Biostatistics (C.E.M.) and MS Center (R.R.L., E.W., S.L.H.), Department of Neurology, University of California, San Francisco; and Department of Neurology (D.T.O.), University of Texas Southwestern, Dallas.
Neurology. 2018 Dec 11;91(24):e2256-e2264. doi: 10.1212/WNL.0000000000006644. Epub 2018 Nov 14.
To determine whether body mass index (BMI) or vitamin D status is associated with MRI measures of neurodegeneration in a cohort of individuals with relapsing-remitting multiple sclerosis (RRMS) or clinically isolated syndrome (CIS).
Expression, Proteomics, Imaging, Clinical (EPIC) is a longitudinal multiple sclerosis (MS) cohort study at the University of California, San Francisco. Participants had clinical evaluations, brain MRI, and blood draws annually. We evaluated patients with CIS or RRMS at baseline. In multivariate repeated-measures analyses adjusted for age, sex, ethnicity, smoking status, and use of MS treatments, annual 25-hydroxyvitamin D levels and BMI were evaluated for their association with subsequent brain volumes (normalized gray matter [nGMV], brain parenchymal [nBPV], and white matter volumes, as determined by Structural Image Evaluation using Normalization of Atrophy-X).
Among 469 participants, each 1-kg/m higher BMI was independently associated with reduced nGMV in multivariate models (-1.1 mL, 95% confidence interval [CI] -1.8 to -0.5, = 0.001). BMI was likewise independently associated with nBPV (nBPV per 1-kg/m greater BMI: -1.1 mL, 95% CI -2.1 to -0.05, = 0.039). Vitamin D levels did not appear to be meaningfully associated with brain volumes.
Higher BMI appears to be associated with greater reductions in nGMV and nBPV, which is relevant because, in particular, nGMV loss portends greater longer-term disability. Because obesity is modifiable, further studies should explore these relationships in detail, and evaluating the effect of reducing BMI on imaging and clinical outcomes in MS may be warranted.
确定体重指数(BMI)或维生素 D 状态是否与复发缓解型多发性硬化症(RRMS)或临床孤立综合征(CIS)患者队列的神经退行性变的 MRI 测量值相关。
表达、蛋白质组学、成像、临床(EPIC)是加利福尼亚大学旧金山分校的一项纵向多发性硬化症(MS)队列研究。参与者每年进行临床评估、脑部 MRI 和血液检查。我们在基线时评估了 CIS 或 RRMS 患者。在调整年龄、性别、种族、吸烟状况和 MS 治疗使用的多变量重复测量分析中,评估了年度 25-羟维生素 D 水平和 BMI 与随后的脑容量(正常化灰质 [nGMV]、脑实质 [nBPV] 和白质体积)之间的关联,通过结构图像评估使用萎缩归一化-X 确定)。
在 469 名参与者中,在多变量模型中,BMI 每增加 1 公斤/平方米,与 nGMV 减少独立相关(-1.1 毫升,95%置信区间 [CI] -1.8 至 -0.5, = 0.001)。BMI 同样与 nBPV 独立相关(每增加 1 公斤/平方米 BMI:-1.1 毫升,95% CI -2.1 至 -0.05, = 0.039)。维生素 D 水平似乎与脑容量没有明显关联。
较高的 BMI 似乎与 nGMV 和 nBPV 的更大减少相关,这很重要,因为特别是 nGMV 的损失预示着更大的长期残疾。由于肥胖是可以改变的,因此应进一步研究详细探讨这些关系,并评估降低 BMI 对 MS 影像学和临床结果的影响是否合理。